This research study is currently not recruiting patients.

A PHASE IIA MULTICENTER OPEN-LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE COMBINATION OF BL-8040 AND PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC PANCREATIC CANCER THE COMBAT STUDY

Brief description of study

The purpose of this clinical study is to learn if BL-8040 given alone followed by combination with pembrolizumab (KEYTRUDA®) and chemotherapy of Onivyde® + 5-FU/LV is safe and effective in treating patients with unresectable metastatic pancreatic cancer. Additional goals of this study are to better understand the mechanism of action of BL-8040.You are being asked to participate in this study because you have been diagnosed with unresectable metastatic pancreatic cancer.


Clinical Study Identifier: s18-01955
ClinicalTrials.gov Identifier: NCT02826486